Number of tablets - Retention at two diffe­rent CROs [Regulatives / Guidelines]

posted by scorp2011 – India, 2014-03-19 13:30 (4487 d 02:08 ago) – Posting: # 12669
Views: 2,991

(edited on 2014-03-19 14:07)

Dear Dr. Dan
Thanks for the clarification.
Yes, these studies are to be conducted according to FDA regulations for an ANDA application. Please note that these two studies (fasting and fed) are to be conducted at two different CRO's. The CRO's are not linked to each other. One is located in India and other is located in US. kindly let me know of your expert opinion over this particular scenario for retention of IP's.
Thanks once again.
Regards
Sonu


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Ohlbe]

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
231 visitors (0 registered, 231 guests [including 22 identified bots]).
Forum time: 16:39 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5